CoChat

Current Status of Clinical Application of Point-of-Care Testing

Park, Hyung-Doo · 2021 · Archives of Pathology & Laboratory Medicine
Cited by 49

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Context.—: The clinical applications of point-of-care testing (POCT) are gradually increasing in many health care systems. Recently, POCT devices using molecular genetic method techniques have been developed. We need to examine clinical pathways to see where POCT can be applied to improve them. Objective.—: To introduce up-to-date POCT items and equipment and to provide the content that should be prepared for clinical application of POCT. Data Sources.—: Literature review based on PubMed searches containing the terms point-of-care testing, clinical chemistry, diagnostic hematology, and clinical microbiology. Conclusions.—: If medical resources are limited, POCT can help clinicians make quick medical decisions. As POCT technology improves and menus expand, areas where POCT can be applied will also increase. We need to understand the limitations of POCT so that it can be optimally used to improve patient management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.5858/arpa.2020-0112-ra

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 112

  1. Kankaanpaa M, Raitakari M, Muukkonen L, et al. Use of point-of-care testing and early assessment model reduces length of stay for ambulatory patients in an emergency department. Scand J Trauma Resusc Emerg Med. 2016; 24(1): 125. · DOI · Paper page
  2. Abel G. Current status and future prospects of point-of-care testing around the globe. Expert Rev Mol Diagn. 2015; 15(7): 853– 855. · DOI
  3. Abbasi U, Chowdhury P, Subramaniam S, et al. A cartridge based point-of-care device for complete blood count. Sci Rep. 2019; 9(1): 18583. · DOI
  4. Smith S, Madzivhandila P, Sewart R, et al. Microfluidic cartridges for automated, point-of-care blood cell counting. SLAS Technol. 2017; 22(2): 176– 185. · doi:10.1177/2211068216677820
  5. Larsson A, Carlsson L, Karlsson B, Lipcsey M. Rapid testing of red blood cell parameters in primary care patients using HemoScreen point of care instrument. BMC Fam Pract. 2019; 20(1): 77. · DOI
  6. Lingervelder D, Koffijberg H, Kusters R, IJzerman MJ. Point-of-care testing in primary care: a systematic review on implementation aspects addressed in test evaluations. Int J Clin Pract. 2019; 73(10): e13392. · DOI
  7. Heneghan C, Ward A, Perera R, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet. 2012; 379(9813): 322– 334. · DOI · Paper page
  8. Crawford F, Andras A, Welch K, Sheares K, Keeling D, Chappell FM. D-dimer test for excluding the diagnosis of pulmonary embolism. Cochrane Database Syst Rev.2016(8):CD010864. · DOI · Paper page
  9. Marquardt U, Apau D. Point-of-care D-dimer testing in emergency departments. Emerg Nurse. 2015; 23(5): 29– 35. · DOI
  10. Sen B, Kesteven P, Avery P. Comparison of D-dimer point of care test (POCT) against current laboratory test in patients with suspected venous thromboembolism (VTE) presenting to the emergency department (ED). J Clin Pathol. 2014; 67(5): 437– 440. · DOI
  11. Perveen S, Unwin D, Shetty AL. Point of care D-dimer testing in the emergency department: a bioequivalence study. Ann Lab Med. 2013; 33(1): 34– 38. · DOI
  12. Lee-Lewandrowski E, Nichols J, Van Cott E, et al. Implementation of a rapid whole blood D-dimer test in the emergency department of an urban academic medical center: impact on ED length of stay and ancillary test utilization. Am J Clin Pathol. 2009; 132(3): 326– 331. · DOI · Paper page
  13. Lucassen WA, Erkens PM, Geersing GJ, et al. Qualitative point-of-care D-dimer testing compared with quantitative D-dimer testing in excluding pulmonary embolism in primary care. J Thromb Haemost. 2015; 13(6): 1004– 1009. · doi:10.1111/jth.12951
  14. Reynolds TM, Pillay TS. Rumsfeld Donald and point-of-care testing (POCT): the problem of unknown unknowns—venous blood and glucose oxidase-based test strips. J Clin Pathol. 2016; 69(10): 839– 840. · DOI
  15. Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14): 977– 986. · DOI · Paper page
  16. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.Lancet. 1998; 352(9131): 837– 853. · DOI · Paper page
  17. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001; 345(19): 1359– 1367. · DOI · Paper page
  18. Petersen JR, Graves DF, Tacker DH, Okorodudu AO, Mohammad AA, Cardenas VJ Jr. Comparison of POCT and central laboratory blood glucose results using arterial, capillary, and venous samples from MICU patients on a tight glycemic protocol. Clin Chim Acta. 2008; 396(1–2): 10– 13. · DOI
  19. Shearer A, Boehmer M, Closs M, et al. Comparison of glucose point-of-care values with laboratory values in critically ill patients. Am J Crit Care. 2009; 18(3): 224– 230. · DOI
  20. Janssen K, Delanghe J. Importance of the pre-analytical phase in blood glucose analysis. Acta Clin Belg. 2010; 65(5): 311– 318. · DOI
  21. Karon BS, Blanshan CT, Deobald GR, Wockenfus AM. Retrospective evaluation of the accuracy of Roche AccuChek Inform and Nova StatStrip glucose meters when used on critically ill patients. Diabetes Technol Ther. 2014; 16(12): 828– 832. · DOI · Paper page
  22. Raizman JE, Shea J, Daly CH, et al. Clinical impact of improved point-of-care glucose monitoring in neonatal intensive care using Nova StatStrip: evidence for improved accuracy, better sensitivity, and reduced test utilization. Clin Biochem. 2016; 49(12): 879– 884. · DOI
  23. Lockyer MG, Fu K, Edwards RM, et al. Evaluation of the Nova StatStrip glucometer in a pediatric hospital setting. Clin Biochem. 2014; 47(9): 840– 843. · DOI
  24. Honiden S, Inzucchi SE. Metabolic management during critical illness: glycemic control in the ICU. Semin Respir Crit Care Med. 2015; 36(6): 859– 869. · DOI
  25. Brady V. Management of hyperglycemia in the intensive care unit: when glucose reaches critical levels. Crit Care Nurs Clin North Am. 2013; 25(1): 7– 13. · DOI
  26. Strasma PJ, Finfer S, Flower O, et al. Use of an intravascular fluorescent continuous glucose sensor in ICU patients. J Diabetes Sci Technol. 2015; 9(4): 762– 770. · DOI
  27. Christiansen MP, Klaff LJ, Brazg R, et al. A prospective multicenter evaluation of the accuracy of a novel implanted continuous glucose sensor: PRECISE II. Diabetes Technol Ther. 2018; 20(3): 197– 206. · DOI · Paper page
  28. Christiansen MP, Klaff LJ, Bailey TS, Brazg R, Carlson G, Tweden KS. A prospective multicenter evaluation of the accuracy and safety of an implanted continuous glucose sensor: the PRECISION study. Diabetes Technol Ther. 2019; 21(5): 231– 237. · DOI · Paper page
  29. Feig DS, Murphy HR. Continuous glucose monitoring in pregnant women with type 1 diabetes: benefits for mothers, using pumps or pens, and their babies. Diabet Med. 2018; 35(4): 430– 435. · DOI
  30. Florkowski C, Crooke M. Standardisation of reporting haemoglobin A1c: adoption of the New Zealand Society for the Study of Diabetes (NZSSD) position statement. N Z Med J. 2010; 123(1310): 43– 49.
  31. Maesa JM, Fernandez-Riejos P, Gonzalez-Rodriguez C, Sanchez-Margalet V. Screening for gestational diabetes mellitus by measuring glycated hemoglobin can reduce the use of the glucose challenge test. Ann Lab Med. 2019; 39(6): 524– 529. · DOI
  32. Miller CD, Barnes CS, Phillips LS, et al. Rapid A1c availability improves clinical decision-making in an urban primary care clinic. Diabetes Care. 2003; 26(4): 1158– 1163. · DOI · Paper page
  33. Schnell O, Crocker JB, Weng J. Impact of HbA1c testing at point of care on diabetes management. J Diabetes Sci Technol. 2017; 11(3): 611– 617. · DOI · Paper page
  34. Al-Ansary L, Farmer A, Hirst J, et al. Point-of-care testing for Hb A1c in the management of diabetes: a systematic review and metaanalysis. Clin Chem. 2011; 57(4): 568– 576. · DOI · Paper page
  35. Thaler LM, Ziemer DC, Gallina DL, et al. Diabetes in urban African-Americans, XVII: availability of rapid HbA1c measurements enhances clinical decision-making. Diabetes Care. 1999; 22(9): 1415– 1421. · DOI · Paper page
  36. Egbunike V, Gerard S. The impact of point-of-care A1C testing on provider compliance and A1C levels in a primary setting. Diabetes Educ. 2013; 39(1): 66– 73. · DOI
  37. Rust G, Gailor M, Daniels E, McMillan-Persaud B, Strothers H, Mayberry R. Point of care testing to improve glycemic control. Int J Health Care Qual Assur. 2008; 21(3): 325– 335. · DOI
  38. Laurence CO, Gialamas A, Bubner T, et al. Patient satisfaction with point-of-care testing in general practice. Br J Gen Pract. 2010; 60(572): e98– e104. · DOI
  39. Crocker JB, Lee-Lewandrowski E, Lewandrowski N, Baron J, Gregory K, Lewandrowski K. Implementation of point-of-care testing in an ambulatory practice of an academic medical center. Am J Clin Pathol. 2014; 142(5): 640– 646. · DOI
  40. Lee-Lewandrowski E, Lewandrowski K. Perspectives on cost and outcomes for point-of-care testing. Clin Lab Med. 2009; 29(3): 479– 489. · DOI
  41. Laurence CO, Moss JR, Briggs NE, Beilby JJ. The cost-effectiveness of point of care testing in a general practice setting: results from a randomised controlled trial. BMC Health Serv Res. 2010; 10: 165. · DOI · Paper page
  42. Chadee A, Blackhouse G, Goeree R. Point-of-care hemoglobin A1c testing: a budget impact analysis. Ont Health Technol Assess Ser. 2014; 14(9): 1– 23.
  43. Lenters-Westra E, Slingerland RJ. Three of 7 hemoglobin A1c point-of-care instruments do not meet generally accepted analytical performance criteria. Clin Chem. 2014; 60(8): 1062– 1072. · DOI · Paper page
  44. Lenters-Westra E, English E. Evaluation of four HbA1c point-of-care devices using international quality targets: are they fit for the purpose? J Diabetes Sci Technol . 2018; 12(4): 762– 770. · DOI
  45. Chung S, Jun SH, Song WH, Song J. Six years' experience of accuracy-based proficiency testing for HbA1c in Korea. Journal of Laboratory Medicine and Quality Assurance. 2015; 37(2): 92– 100. · DOI
  46. Solvik UO, Bjelkaroy WI, Berg KVD, Saga AL, Hager HB, Sandberg S. Intensive educational efforts combined with external quality assessment improve the preanalytical phase in general practitioner offices and nursing homes. Clin Chem Lab Med. 2017; 55(12): 1857– 1864. · DOI
  47. Regan B, Boyle F, O'Kennedy R, Collins D. Evaluation of molecularly imprinted polymers for point-of-care testing for cardiovascular disease. Sensors (Basel). 2019; 19(16). · DOI
  48. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Circulation. 2018; 138(20): e618– e651.
  49. Bingisser R, Cairns C, Christ M, et al. Cardiac troponin: a critical review of the case for point-of-care testing in the ED. Am J Emerg Med. 2012; 30(8): 1639– 1649. · DOI
  50. Florkowski C, Don-Wauchope A, Gimenez N, Rodriguez-Capote K, Wils J, Zemlin A. Point-of-care testing (POCT) and evidence-based laboratory medicine (EBLM)—does it leverage any advantage in clinical decision making? Crit Rev Clin Lab Sci . 2017; 54(7–8): 471– 494. · DOI · Paper page
  51. Peacock WF, Diercks D, Birkhahn R, et al. Can a point-of-care Troponin I Assay be as good as a central laboratory assay?: a MIDAS investigation. Ann Lab Med. 2016; 36(5): 405– 412. · doi:10.3343/alm.2016.36.5.405
  52. Collinson P, Goodacre S, Gaze D, Gray A. Very early diagnosis of chest pain by point-of-care testing: comparison of the diagnostic efficiency of a panel of cardiac biomarkers compared with troponin measurement alone in the RATPAC trial. Heart. 2012; 98(4): 312– 318. · DOI
  53. Vafaie M, Biener M, Mueller M, et al. Addition of copeptin improves diagnostic performance of point-of-care testing (POCT) for cardiac troponin T in early rule-out of myocardial infarction—a pilot study. Int J Cardiol. 2015; 198: 26– 30. · DOI
  54. Bingisser R, Cairns CB, Christ M, et al. Measurement of natriuretic peptides at the point of care in the emergency and ambulatory setting: current status and future perspectives. Am Heart J. 2013; 166(4): 614– 621.e611. · DOI
  55. Iwaz JA, Maisel AS. Recent advances in point-of-care testing for natriuretic peptides: potential impact on heart failure diagnosis and management. Expert Rev Mol Diagn. 2016; 16(6): 641– 650. · DOI
  56. Bogaert L, Schiemsky T, Van Hover P, De Schrijver P, Van Hoovels L. Analytical and diagnostic performance evaluation of five creatinine POCT devices in the identification of patients at risk for post-contrast acute kidney injury (PCAKI). Clin Chem Lab Med. 2019; 57(9): e214– e217. · doi:10.1515/cclm-2018-1105
  57. Snaith B, Harris MA, Shinkins B, Jordaan M, Messenger M, Lewington A. Point-of-care creatinine testing for kidney function measurement prior to contrast-enhanced diagnostic imaging: evaluation of the performance of three systems for clinical utility. Clin Chem Lab Med. 2018; 56(8): 1269– 1276. · DOI
  58. van der Heijden C, Roosens L, Cluckers H, Van Craenenbroeck AH, Peeters B. Analytical and clinical performance of three hand-held point-of-care creatinine analyzers for renal function measurements prior to contrast-enhanced imaging. Clin Chim Acta. 2019; 497: 13– 19. · DOI
  59. Niska R, Bhuiya F, Xu J. National Hospital Ambulatory Medical Care Survey: 2007 emergency department summary. Natl Health Stat Report. 2010;(26):1–31. · DOI · Paper page
  60. Braunstein GD. The long gestation of the modern home pregnancy test. Clin Chem. 2014; 60(1): 18– 21. · doi:10.1373/clinchem.2013.202655
  61. Nerenz RD, Song H, Gronowski AM. Screening method to evaluate point-of-care human chorionic gonadotropin (hCG) devices for susceptibility to the hook effect by hCG beta core fragment: evaluation of 11 devices. Clin Chem. 2014; 60(4): 667– 674. · DOI
  62. Nerenz RD, Gronowski AM. Point-of-care and over-the-counter qualitative human chorionic gonadotropin (hCG) devices remain susceptible to false-negative results caused by excess hCG beta core fragment. Clin Chem. 2013; 59(11): 1672– 1674. · doi:10.1373/clinchem.2013.212795
  63. Gronowski AM, Powers M, Stenman UH, Ashby L, Scott MG. False-negative results from point-of-care qualitative human chorionic gonadotropin (hCG) devices caused by excess hCGbeta core fragment vary with device lot number. Clin Chem. 2009; 55(10): 1885– 1886. · doi:10.1373/clinchem.2009.133280
  64. Gronowski AM, Cervinski M, Stenman UH, Woodworth A, Ashby L, Scott MG. False-negative results in point-of-care qualitative human chorionic gonadotropin (hCG) devices due to excess hCGbeta core fragment. Clin Chem. 2009; 55(7): 1389– 1394. · DOI
  65. Griffey RT, Trent CJ, Bavolek RA, Keeperman JB, Sampson C, Poirier RF. “Hook-like effect” causes false-negative point-of-care urine pregnancy testing in emergency patients. J Emerg Med. 2013; 44(1): 155– 160. · doi:10.1016/j.jemermed.2011.05.032
  66. Nickmans S, Vermeersch P, Van Eldere J, Billen J. Performance of qualitative urinary hCG assays. Acta Clin Belg. 2014; 69(4): 277– 279. · doi:10.1179/0001551214z.00000000069
  67. Greene DN, Schmidt RL, Kamer SM, Grenache DG, Hoke C, Lorey TS. Limitations in qualitative point of care hCG tests for detecting early pregnancy. Clin Chim Acta. 2013; 415: 317– 321. · DOI
  68. Terwijn M, van Schie A, Blankenstein MA, Heijboer AC. Pregnancy detection by quantitative urine hCG analysis: the need for a lower cut-off. Clin Chim Acta. 2013; 424: 174. · doi:10.1016/j.cca.2013.06.010
  69. Kamer SM, Foley KF, Schmidt RL, Greene DN. Analytical sensitivity of four commonly used hCG point of care devices. Clin Biochem. 2015; 48(6): 448– 452. · doi:10.1016/j.clinbiochem.2014.12.015
  70. Tenenbein M. Do you really need that emergency drug screen? Clin Toxicol (Phila) . 2009; 47(4): 286– 291. · DOI
  71. Mastrovitch TA, Bithoney WG, DeBari VA, Nina AG. Point-of-care testing for drugs of abuse in an urban emergency department. Ann Clin Lab Sci. 2002; 32(4): 383– 386.
  72. Attema-de Jonge ME, Peeters SY, Franssen EJ. Performance of three point-of-care urinalysis test devices for drugs of abuse and therapeutic drugs applied in the emergency department. J Emerg Med. 2012; 42(6): 682– 691. · DOI
  73. Tomaszewski C, Runge J, Gibbs M, Colucciello S, Price M. Evaluation of a rapid bedside toxicology screen in patients suspected of drug toxicity. J Emerg Med. 2005; 28(4): 389– 394. · DOI
  74. Zhang Y, Kwong TC. Utilization management in toxicology. Clin Chim Acta. 2014; 427: 158– 166. · DOI
  75. Wiencek JR, Colby JM, Nichols JH. Rapid assessment of drugs of abuse. Adv Clin Chem. 2017; 80: 193– 225. · DOI
  76. Wang LL, Ren XX, He Y, Cui GF, Wei ZW, Yun KM. An experimental pharmacokinetics study of diazepam and its metabolites in oral fluid of Chinese population [published online January 21, 2020]. J Anal Toxicol. doi:10.1093/jat/bkz101 · DOI
  77. Scherer JN, Fiorentin TR, Borille BT, et al. Reliability of point-of-collection testing devices for drugs of abuse in oral fluid: a systematic review and meta-analysis. J Pharm Biomed Anal. 2017; 143: 77– 85. · DOI
  78. Wagmann L, Maurer HH. Bioanalytical methods for new psychoactive substances. Handb Exp Pharmacol. 2018; 252: 413– 439. · DOI
  79. Nichols JH, Christenson RH, Clarke W, et al. Executive summary: the National Academy of Clinical Biochemistry Laboratory Medicine Practice Guideline: evidence-based practice for point-of-care testing. Clin Chim Acta. 2007; 379(1–2): 14– 28; discussion 29–30. · doi:10.1016/j.cca.2006.12.027
  80. Zeserson E, Goodgame B, Hess JD, et al. Correlation of venous blood gas and pulse oximetry with arterial blood gas in the undifferentiated critically ill patient. J Intensive Care Med. 2018; 33(3): 176– 181. · DOI
  81. Schrauben SJ, Negoianu D, Costa C, et al. Accuracy of acid-base diagnoses using the central venous blood gas in the medical intensive care unit. Nephron. 2018; 139(4): 293– 298. · doi:10.1159/000488501
  82. Ekstrom M, Engblom A, Ilic A, Holthius N, Nordstrom P, Vaara I. Calculated arterial blood gas values from a venous sample and pulse oximetry: clinical validation. PLoS One. 2019; 14(4): e0215413. · DOI
  83. Mirzazadeh M, Morovat A, James T, Smith I, Kirby J, Shine B. Point-of-care testing of electrolytes and calcium using blood gas analysers: it is time we trusted the results. Emerg Med J. 2016; 33(3): 181– 186. · DOI · Paper page
  84. Triplett KE, Wibrow BA, Norman R, et al. Can the blood gas analyser results be believed? A prospective multicentre study comparing haemoglobin, sodium and potassium measurements by blood gas analysers and laboratory auto-analysers. Anaesth Intensive Care. 2019; 47(2): 120– 127. · DOI
  85. Gibbons M, Klim S, Mantzaris A, Dillon O, Kelly AM. How closely do blood gas electrolytes and haemoglobin agree with serum values in adult emergency department patients: an observational study. Emerg Med Australas. 2019; 31(2): 241– 246. · DOI
  86. Kankaanpaa M, Holma-Eriksson M, Kapanen S, et al. Comparison of the use of comprehensive point-of-care test panel to conventional laboratory process in emergency department. BMC Emerg Med. 2018; 18(1): 43. · DOI
  87. Van den Bruel A, Thompson MJ, Haj-Hassan T, et al. Diagnostic value of laboratory tests in identifying serious infections in febrile children: systematic review. BMJ. 2011; 342:d3082. · DOI · Paper page
  88. Chaisson LH, Semitala FC, Asege L, et al. Point-of-care C-reactive protein and risk of early mortality among adults initiating antiretroviral therapy. AIDS. 2019; 33(5): 895– 902. · DOI
  89. Brouwer N, van Pelt J. Validation and evaluation of eight commercially available point of care CRP methods. Clin Chim Acta. 2015; 439: 195– 201. · DOI
  90. Na JY, Park JT. Evaluation of point-of-care testing for C-reactive protein in forensic medicine. J Korean Med Sci. 2019; 34(38): e246. · doi:10.3346/jkms.2019.34.e246
  91. Thaler M, Luppa PB. Highly sensitive immunodiagnostics at the point of care employing alternative recognition elements and smartphones: hype, trend, or revolution? Anal Bioanal Chem . 2019; 411(29): 7623– 7635. · DOI
  92. Bulterys MA, Wagner B, Redard-Jacot M, et al. Point-of-care urine LAM tests for tuberculosis diagnosis: a status update [published online December 31, 2019]. J Clin Med. 2020; 9(1): 111. doi:10.3390/jcm9010111 · DOI · Paper page
  93. Kim H, Chung DR, Kang M. A new point-of-care test for the diagnosis of infectious diseases based on multiplex lateral flow immunoassays. Analyst. 2019; 144(8): 2460– 2466. · DOI · Paper page
  94. Qin Q, Wang K, Yang J, et al. Algorithms for immunochromatographic assay: review and impact on future application. Analyst. 2019; 144(19): 5659– 5676. · DOI
  95. Egilmezer E, Walker GJ, Bakthavathsalam P, et al. Systematic review of the impact of point-of-care testing for influenza on the outcomes of patients with acute respiratory tract infection. Rev Med Virol. 2018; 28(5): e1995. · DOI · Paper page
  96. Popowitch EB, Miller MB. Performance characteristics of Xpert Flu/RSV XC assay. J Clin Microbiol. 2015; 53(8): 2720– 2721. · doi:10.1128/jcm.00972-15
  97. Wahrenbrock MG, Matushek S, Boonlayangoor S, Tesic V, Beavis KG, Charnot-Katsikas A. Comparison of Cepheid Xpert Flu/RSV XC and BioFire FilmArray for detection of influenza A, influenza B, and respiratory syncytial virus. J Clin Microbiol. 2016; 54(7): 1902– 1903. · DOI
  98. Nitsch-Osuch A, Kuchar E, Golebiak I, Kanecki K, Tarka P, Brydak LB. Rapid influenza diagnostic tests improve suitability of antiviral treatment in hospitalized children. Adv Exp Med Biol. 2017; 968: 1– 6. · doi:10.1007/5584_2016_181
  99. Brendish NJ, Malachira AK, Armstrong L, et al. Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial. Lancet Respir Med. 2017; 5(5): 401– 411. · DOI · Paper page
  100. Li-Kim-Moy J, Dastouri F, Rashid H, et al. Utility of early influenza diagnosis through point-of-care testing in children presenting to an emergency department. J Paediatr Child Health. 2016; 52(4): 422– 429. · doi:10.1111/jpc.13092
  101. Brendish NJ, Schiff HF, Clark TW. Point-of-care testing for respiratory viruses in adults: the current landscape and future potential. J Infect. 2015; 71(5): 501– 510. · DOI
  102. Brendish NJ, Mills S, Ewings S, Clark TW. Impact of point-of-care testing for respiratory viruses on antibiotic use in adults with exacerbation of airways disease. J Infect. 2019; 79(4): 357– 362. · doi:10.1016/j.jinf.2019.06.010
  103. Chavez PR, Bradley HM, Wesolowski LG, et al. Performance evaluation of four point-of-care HIV tests using unprocessed specimens. J Clin Virol. 2020; 124: 104282. · doi:10.1016/j.jcv.2020.104282
  104. Pai NP, Tulsky JP, Cohan D, Colford JM Jr, Reingold AL. Rapid point-of-care HIV testing in pregnant women: a systematic review and meta-analysis. Trop Med Int Health. 2007; 12(2): 162– 173. · DOI · Paper page
  105. Dalcin D, Bogoch II. Point-of-care testing for HIV. CMAJ. 2018; 190(18): E569. · DOI
  106. Gliddon HD, Peeling RW, Kamb ML, Toskin I, Wi TE, Taylor MM. A systematic review and meta-analysis of studies evaluating the performance and operational characteristics of dual point-of-care tests for HIV and syphilis. Sex Transm Infect. 2017; 93(S4): S3– S15. · DOI · Paper page
  107. Negedu-Momoh OR, Jegede FE, Yakubu A, et al. Performance evaluation of BD FACSPresto point of care CD4 analyzer to enumerate CD4 counts for monitoring HIV infected individuals in Nigeria. PLoS One. 2017; 12(5): e0178037. · doi:10.1371/journal.pone.0178037
  108. Moran Z, Sacks JA, Frimpong FK, Frimpong AB, Ben Amor Y. Performance of the BD-FACS Presto for CD4 count and hemoglobin measurement in a district hospital and rural laboratory in Ghana. PLoS One. 2019; 14(2): e0212684. · doi:10.1371/journal.pone.0212684
  109. Bwana P, Vojnov L, Adhiambo M, et al. The BD FACSPresto point of care CD4 test accurately enumerates CD4+ T cell counts. PLoS One. 2015; 10(12): e0145586. · DOI
  110. Hong KH, Lee SW, Kim TS, et al. Guidelines for laboratory diagnosis of coronavirus disease 2019 (COVID-19) in Korea. Ann Lab Med. 2020; 40(5): 351– 360. · DOI · Paper page
  111. Imai K, Tabata S, Ikeda M, et al. Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19. J Clin Virol. 2020; 128: 104393. · DOI
  112. Brendish NJ, Malachira AK, Clark TW. Molecular point-of-care testing for respiratory viruses versus routine clinical care in adults with acute respiratory illness presenting to secondary care: a pragmatic randomised controlled trial protocol (ResPOC). BMC Infect Dis. 2017; 17(1): 128. · DOI

Metadata

Authors
Park, H.-D.
Venue
Archives of Pathology & Laboratory Medicine
Published
2020-10-14
Volume
145
Issue
2
Pages
168-175
ISSN
  • 1543-2165
  • 0003-9985
Cited by
49
References
8
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current Status of Clinical Application of Point-of-Care Testing. https://app.cochat.ai/papers/10.5858/arpa.2020-0112-ra
The paper
Park, H.-D. (2021). Current Status of Clinical Application of Point-of-Care Testing. Archives of Pathology & Laboratory Medicine. https://doi.org/10.5858/arpa.2020-0112-ra

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.